SCHEMBL2432422

SCHEMBL2432422

CC1(C(N)=O)CCCC(C)(C2=Cc3ccccc3NC2)C1=O

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437368 0.73 SIRT1 (0.31)
SCHEMBL2427124 0.70 HSD17B3 (0.30) MEN1KMT2A
SCHEMBL2434332 0.70
SCHEMBL5473668 0.70 BRPF1 (0.31) MEN1KMT2A
SCHEMBL2435594 0.66 IDO1 (0.35) MEN1KMT2A
SCHEMBL2431727 0.65 PDK1 (0.32)
SCHEMBL5473904 0.65 BRPF1 (0.30)
SCHEMBL2435591 0.64 KDM4E (0.32)
SCHEMBL2427131 0.64
SCHEMBL5483296 0.64 HSD17B3 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212946-A1 Quinolone Neuropeptide S Receptor Antagonists MERCK SHARP & DOHME LLC 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212946-A1 Quinolone Neuropeptide S Receptor Antagonists NPSR1, NPY1R, NPY2R MEN1 1784/4885KMT2A 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.